Savara Inc. - SVRA STOCK NEWS

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, has announced the grant of inducement awards to a new employee. The Compensation Committee of Savara's Board of Directors granted these awards on September 5, 2024, consisting of:

• Options to purchase 20,000 shares of the Company's common stock
• Restricted stock units (RSUs) covering 20,000 shares of the Company's common stock

The options have an exercise price of $4.54 per share, a 10-year term, and vest quarterly over 4 years. The RSUs vest in full after two years. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management team is scheduled to present on September 10, 2024, at 10:00 AM ET / 7:00 AM PT.

Investors and interested parties can access a live webcast of the presentation through Savara's official website at www.savarapharma.com/investors/events-presentations/. The webcast will remain archived for 90 days after the event, allowing those unable to attend the live presentation to review the content later.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, has announced inducement awards for a new employee. The Compensation Committee granted these awards on August 15, 2024, consisting of:

1. Options to purchase 20,000 shares of common stock
2. Restricted stock units (RSUs) covering 20,000 shares of common stock

These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan. The options have an exercise price of $4.51 per share, vesting quarterly over four years. The RSUs vest fully after two years, subject to continued employment.

Savara Inc. (Nasdaq: SVRA) announced the acceptance of an abstract for poster presentation at the European Respiratory Society (ERS) Congress 2024, taking place September 7-11, 2024, in Vienna, Austria. The abstract, titled "Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2", will be presented on September 8, 2024.

Additionally, Savara is sponsoring an Industry Symposium titled "Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management" on the same day. The symposium will feature speakers Cormac McCarthy, Elisabeth Bendstrup, and Francesco Bonella, all holding M.D. and Ph.D. degrees.

Savara Inc. (Nasdaq: SVRA) reported positive top-line results from the IMPALA-2 Phase 3 trial of molgramostim for treating autoimmune pulmonary alveolar proteinosis (aPAP). The trial met its primary endpoint, showing statistically significant improvement in lung diffusing capacity at 24 weeks. Key secondary endpoints were also met, including improvements in respiratory quality of life.

The FDA conditionally accepted the trade name MOLBREEVI™ for molgramostim. Savara plans to complete the BLA submission in H1 2025. The company raised ~$100M in equity financing in July 2024, bringing its total cash position to over $200M, expected to fund operations through 2026.

For Q2 2024, Savara reported a net loss of $22.2M, or $(0.12) per share. R&D expenses increased 97.7% YoY to $17.6M, while G&A expenses rose 67.8% to $5.5M.

Savara, a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at $3.81 per share. This offering aims to raise approximately $100.0 million before deducting underwriting discounts and commissions. The offering involves notable investors such as Bain Capital Life Sciences and Wellington Management and is expected to close on July 1, 2024, subject to customary conditions. Jefferies, Piper Sandler, and Guggenheim Securities are the joint book-running managers, with Oppenheimer & Co. as the lead manager. The offering is conducted under Savara's existing shelf registration statement filed with the SEC. Detailed prospectus information can be obtained from the involved financial institutions or the SEC website.

Savara announced positive results from its pivotal Phase 3 IMPALA-2 trial of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim showed statistically significant improvements in lung function (DLCO) versus placebo at both Week 24 and Week 48. Additionally, improvements were seen in St. George’s Respiratory Questionnaire (SGRQ) scores at Week 24. Notably, 97% of patients completed the 48-week double-blind treatment with no trial drug-related discontinuations. The company plans to complete the Biologics License Application submission by the first half of 2025. Molgramostim was well tolerated with similar adverse event frequencies between treatment groups. Savara will host a webcast conference call to discuss these results.

Savara, a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, will host a conference call and webcast on June 26, 2024, at 8:00am ET to discuss the top line results from its pivotal Phase 3 IMPALA-2 trial. This trial assesses the safety and efficacy of molgramostim, an inhaled GM-CSF, in treating autoimmune pulmonary alveolar proteinosis (aPAP). A press release detailing these results will be issued at 6:30am ET on the same day, prior to the call. Stakeholders can access the live webcast through Savara's website or by phone registration, with a replay available for 90 days.

Savara, a clinical stage biopharmaceutical company focusing on rare respiratory diseases, announced its participation in the Jefferies Global Healthcare Conference. The management team will engage in a fireside chat scheduled for June 5, 2024, at 7:00am PT/10:00am ET. The event will be live-streamed on Savara's website and will remain accessible for 90 days. This conference is a significant platform for industry exposure, potentially impacting SVRA stock performance.